Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/1999
10/21/1999WO1999052889A1 (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides
10/21/1999WO1999052887A1 7-hexanoyltaxol and methods for preparing the same
10/21/1999WO1999052869A1 Substituted indolinones having an inhibiting effect on kinases and cycline/cdk complexes
10/21/1999WO1999052868A1 Substituted pyrrolidine hydroxamate metalloprotease inhibitors
10/21/1999WO1999052862A1 Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors
10/21/1999WO1999052562A2 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
10/21/1999WO1999052552A1 T cell inhibitory receptor compositions and uses thereof
10/21/1999WO1999052549A1 Adjuvant compositions
10/21/1999WO1999052546A2 A method of inducing an anti-tumor response against a lung metastasis in a melanoma patient
10/21/1999WO1999052543A2 Pharmaceutical compositions comprising erythropoietin for treatment of cancer
10/21/1999WO1999052541A2 Artery- and vein-specific proteins and uses therefor
10/21/1999WO1999052534A1 Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
10/21/1999WO1999052521A1 Spisulosine compounds having antitumour activity
10/21/1999WO1999052514A2 Pharmaceutical composition and combination preparation for immunosuppressive therapy
10/21/1999WO1999052493A2 Compounds that inhibit the binding of integrins to their receptors
10/21/1999WO1999043676A3 6,9-disubstituted 2-[trans-(4- aminocyclohexyl) amino]purines
10/21/1999WO1999042593A8 Compositions and methods for sensitizing and inhibiting growth of human tumor cells
10/21/1999WO1999042137A3 Stress promoter control of therapeutic genes in gene therapy: compositions and methods
10/21/1999WO1999040925A3 Hapten-modified tumor cell membranes and their use
10/21/1999WO1999039746A3 Radioactive seed implants
10/21/1999WO1999036105A9 USE OF RADIOLABELED MONOCLONAL IgM IN THERAPY FOR CANCER AND AUTOIMMUNE DISEASE
10/21/1999WO1999033870A3 Human regulatory proteins
10/21/1999WO1999030157A9 Neuropilins in methods for diagnosis and prognosis of cancer
10/21/1999WO1999015654A3 Tie receptor tyrosine kinase ligand homologues
10/21/1999DE19817946A1 New nucleic acid sequences expressed in normal uterine tissues, and derived polypeptides, for treatment of uterine cancer and identification of therapeutic agents
10/21/1999DE19817557A1 Menschliche Nukleinsäuresequenzen aus Ovartumorgewebe Human nucleic acid sequences from Ovartumorgewebe
10/21/1999DE19817461A1 New benzamide derivatives useful as cysteine protease inhibitors for treating neurodegenerative diseases, neuronal damage, stroke, cranial trauma, Alzheimer's disease, etc.
10/21/1999DE19816624A1 Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel New substituted indolinones, their preparation and their use as medicaments
10/21/1999CA2369172A1 Ste20-related protein kinases
10/21/1999CA2328725A1 T cell inhibitory receptor compositions and uses thereof
10/21/1999CA2328211A1 Substituted pyrrolidine hydroxamate metalloprotease inhibitors
10/21/1999CA2328126A1 Spisulosine compounds having antitumour activity
10/21/1999CA2327791A1 7-hexanoyltaxol and methods for preparing the same
10/21/1999CA2327782A1 Azabicyclic 5ht1 receptor ligands
10/21/1999CA2327516A1 Programmed cell death and caspase-12
10/21/1999CA2327431A1 Pharmaceutical composition
10/21/1999CA2327339A1 A method of inducing an anti-tumor response against a lung metastasis in a melanoma patient
10/21/1999CA2326665A1 Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists
10/21/1999CA2325939A1 Vaccine
10/21/1999CA2325824A1 Tao protein kinases and methods of use therefor
10/21/1999CA2325563A1 Artery- and vein-specific proteins and uses therefor
10/21/1999CA2321181A1 Use of monocytes derived cells, antigens and antibodies for optimal induction of immunotherapeutic efficiency
10/21/1999CA2293453A1 13-dihydro-3'aziridino anthracyclines
10/20/1999EP0950709A1 Antisense oligonucleotides for the inhibition of integrin alphaV-subunit expression
10/20/1999EP0950666A1 Diagnostic and Therapy of diseases linked with HHV-8 infection with antibody against Kaposin or with Kaposin-derivated-peptides
10/20/1999EP0950657A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitors
10/20/1999EP0950656A1 Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
10/20/1999EP0950105A1 Tnf-beta-like protein for treating prostate cancer, and related nucleic acid molecules, pharmaceutical compositions and methods
10/20/1999EP0950103A2 Survivin, a protein that inhibits cellular apoptosis, and its modulation
10/20/1999EP0950096A1 Anti-invasive and anti-angiogenic urokinase fragments and their use
10/20/1999EP0950059A1 Cyclic sulfone derivatives
10/20/1999EP0950054A1 Substituted heterocycles as anti-tumor agents
10/20/1999EP0950046A1 3,4-disubstituted azetidin-2-one derivatives useful as cysteine proteinase regulators
10/20/1999EP0949918A1 7-deoxy-6-substituted paclitaxels
10/20/1999EP0949917A1 Substances and their uses
10/20/1999EP0783318A4 Inhibitors of farnesyl-protein transferase
10/20/1999EP0766689B1 Novel oligosaccharide derivatives, preparation method therefor and uses thereof
10/20/1999EP0740655B1 Metalloproteinase inhibitors
10/20/1999CN1232505A Nucleic acid sequences that encode cell growth regulatory protein and uses thereof
10/20/1999CN1232503A Tumor necrosis factor related ligand
10/20/1999CN1232501A Modified TIE-2 -receptor ligands
10/20/1999CN1232498A Guanine exchange factor of RHO GTPase and nucleic acid encoding it
10/20/1999CN1232467A Isolated nucleic acid molecule encoding cancer associated antigen, antigen itself, and uses thereof
10/20/1999CN1232457A 1,4-heterocyclic metalloprotease inhibitors
10/20/1999CN1232451A Substd. cyclic amine metalloprotease inhibitors
10/20/1999CN1232448A Vitamin D analogues
10/20/1999CN1232402A Method and compositions for immunomodulation
10/20/1999CN1232399A Inhibitors of cysteine protease
10/20/1999CN1232395A Pharmaceutical compound comprising polyamines substd. with electron-affinic groups
10/20/1999CN1232028A Derivatives of phenoxy acetic acid and of phenoxymethyl tetrazole having antitumor activity
10/20/1999CN1231922A Medicine for treatment of cancer
10/19/1999US5969190 Cyclohexanediol derivatives
10/19/1999US5969125 Polynucleotideds that encode polypeptides that can be used to generate antibodies to prevent, treat, and reduce effects of disease
10/19/1999US5969120 Dna molecule with synthetically mutated retinoblastoma gene encoding a mutated protein; therapy for a tumor cell with mutation in cyclin gene; antitumor agents
10/19/1999US5969117 Modified protein kinase a-specific oligonucleotide
10/19/1999US5969110 Antibodies which are immunoreactive with a human tyrosine kinase ligand protein
10/19/1999US5969107 Monoclonal antibody containing antigen recognition sites which mimic antigenic regions of receptors; diagnostic and therapeutic tool for treatment of tumors
10/19/1999US5969105 Stem cell factor receptor agonists
10/19/1999US5969093 Secreted proteins
10/19/1999US5968978 Antiarrythmia agents, antiischemic agents, inhibit proliferation of cells
10/19/1999US5968972 Administering a cyclosporin and paclitaxel or salt
10/19/1999US5968952 Farnesyl transferase inhibiting 2-quinolone derivatives
10/19/1999US5968945 Immunotherapeutic agents
10/19/1999US5968931 Taxoids, preparation thereof and pharmaceutical compositions containing same
10/19/1999US5968914 Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
10/19/1999US5968909 Method of modulating gene expression with reduced immunostimulatory response
10/19/1999US5968903 Helicobacter and antigrowth agents, using somatostatin or agonist
10/19/1999US5968895 Solid ionic complexes of luteinizing hormone releasing hormone analogues(active peptides) and anionic polymer carriers, also for stable suspensions or dispersions(not microencapsulated), for treatment of prostate cancer
10/19/1999US5968894 Verotoxin pharmaceutical compositions and medical treatments therewith
10/19/1999US5968826 Antisense inhibition of integrin α4 expression
10/19/1999US5968825 Antisense oligonucleotides complementary to the primary transcript of the human c-fes protooncogene
10/19/1999US5968824 Administering agent which modulates biochemical pathway in which products of opioid peptide precursor genes participate; antitumor agents; prevention of opacity of intraocular lens after cataract surgery
10/19/1999US5968822 Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells
10/19/1999US5968747 Polynucleotide encoding polypeptide; therapy for prevention and treatment of cancer, autoimmune diseases, developmental defects, nervous system disorders
10/19/1999US5968737 Method of identifying inhibitors of glutathione S-transferase (GST) gene expression
10/19/1999US5968734 Dna sequences that migrate to new genetic positions and the fusion products; diagnosis of carcinomas, melanomas, and sarcomas suchas ewing's sarcoma
10/19/1999US5968567 Method of preparing a food product from cruciferous sprouts
10/19/1999US5968524 Methods and compounds for the treatment of immunologically-mediated psoriasis
10/19/1999US5968511 ErbB3 antibodies
10/19/1999US5968509 Antibodies with binding affinity for the CD3 antigen
1 ... 1944 1945 1946 1947 1948 1949 1950 1951 1952 1953 1954 1955 1956 1957 1958 1959 1960 1961 1962 1963 1964 ... 2211